Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, February 24, 2023
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
Andrew Fein Reiterated (CCCC) at Strong Buy and Held Target at $35 on, Feb 24th, 2023
Andrew Fein of HC Wainwright & Co., Reiterated "C4 Therapeutics, Inc." (CCCC) at Strong Buy and Held Target at $35 on, Feb 24th, 2023.
Andrew has made no other calls on CCCC in the last 4 months.
There is 1 other peer that has a rating on CCCC. Out of the 1 peers that are also analyzing CCCC, all agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Derek Archila of "Wells Fargo" Maintained at Hold with Decreased Target to $9 on, Tuesday, January 3rd, 2023
